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Abstract: Background: the presence of liver metastasis in colorectal cancer (CRC) remains one of the
most significant prognostic factors. Objective: systematically review the results of studies evaluating
the benefit of adding bevacizumab to a normal chemotherapy regime in the survival of patients with
colorectal-cancer liver metastasis (CRLM). Search methods: Pubmed and Google Scholar databases
were searched for eligible articles (from inception up to the 2 April 2019). Inclusion criteria: studies
including patients with CRLM receiving anti-vascular endothelial growth factor (VEGF; bevacizumab)
as treatment, overall survival as an outcome; regarding language restrictions, only articles in English
were accepted. Main results: Eleven studies met the inclusion criteria. In 73% of these cases,
chemotherapy with bevacizumab was an effective treatment modality for treating CRLM, and its
administration significantly extended both overall survival (OS) and/or progression-free survival
(PFS). Nevertheless, three articles showed no influence on survival rates of bevacizumab-associated
chemotherapy. Author conclusions: It is necessary to standardize methodologies that aim to evaluate
the impact of bevacizumab administration on the survival of patients with CRLM. Furthermore,
follow-up time and the cause of a patient’s death should be recorded, specified, and cleared in order
to better calculate the survival rate and provide a comparison between the produced literature.
Keywords: anti-VEGF; colorectal cancer; hepatic metastasis; survival
1. Introduction
Colorectal cancer (CRC) represents a major public-health issue. There were more than 1.3 million
new CRC cases in 2012, accounting for nearly 10% of the cancers [1]. It is now estimated that there are
about 3.5 million people in the world with CRC, and that about 600,000 deaths occur each year (8% of
all deaths from malignant neoplasms) [1]. It is the third most common cancer in men, and second in
women, with an estimated CRC five-year survival rate of 65% in North America and 54% in Western
Europe [2].
Liver metastasis from CRC remains one of the most significant prognostic factors for the treatment
outcome. At the time of resection of the primary tumor, about 25% of patients with CRC already have
liver metastases, and over the course of the disease, at least approximately 50% of patients develop
liver metastasis.
CRC management has evolved into a multidisciplinary approach; when disease has spread to
the surrounding lymph nodes, and even distant metastasis, a combination of chemotherapy, targeted
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molecular-therapy agents, radiation, and surgical procedures for resectable metastasis have markedly
improved overall survival (OS) [3]. Even so, surgical resection is the only potentially curative option in
CRC liver-metastasis (CRLM) management [4].
Unfortunately, the major part of patients with CRLM are considered to be unresectable at
presentation because of extrahepatic-disease involvement or insufficient remaining healthy liver
tissue [5].
In order to solve this issue, there has been an increased use of chemotherapy before potentially
curative surgery. Neoadjuvant chemotherapy has a number of potential advantages, including the
possibility for previously unresectable tumors to become resectable; downsizing the tumor and
increasing the chance of curative resection; determining tumor chemoresponsiveness to help select
optimal adjuvant therapy, and identifying patients with a particularly aggressive disease in whom
surgery would be inappropriate; in patients considered as resectable, neoadjuvant chemotherapy may
treat undetected distant micrometastatic disease, thus reducing the risk of recurrence after resection.
Currently, treatment consists of a fluoropyrimidine doublet (FOLFOXCAPOX or FOLFIRI/CAPIRI)
or fluoropyrimidine monotherapy (5-FU/folinic acid or capecitabine) in combination with a biological
agent specific for vascular endothelial growth factor (VEGF) [6]. Current studies state that FOLFIRI
and FOLFOX are identical in terms of efficacy, but vary in toxicity [6].
Monoclonal antibodies such as bevacizumab are part of the new generation of drugs in oncology,
and have led to an improvement in disease prognosis, which has allowed the appearance of bases for
research on the impact of biological therapy in CRLM treatment [7].
In the last few years, bevacizumab, a humanized immunoglobulin G1 monoclonal antibody
targeting VEGF-A [8], was introduced in CRC treatment alongside chemotherapy [7]. It inhibits
neovascularization, an essential mechanism for the growth and self-sustainability of tumors, and
the vascular endothelial growth factor is one of the most important proangiogenic factors in both
physiological and pathological conditions. When bevacizumab is coupled with VEGF, it deactivates its
binding to the vascular endothelial growth factor receptor (VEGFR); therefore, it compromises the
survival of cancer cells, inhibiting their growth [1]. However, further studies are needed to better
understand the effective role of bevacizumab in survival, and its significance [1].
VEGF-A is the most studied member of the VEGF family, which also includes VEG-B, VEGF-C,
VEGF-D, VEGF-E, and placental growth factor (PLGF).
The aim of this paper was to systematically review the results of studies evaluating the benefit of
adding bevacizumab to a normal chemotherapy regime in the survival of patients with CRLM.
2. Results
Research summary is presented in Figure 1. We initially retrieved 258 potentially relevant reports,
from which we excluded 238 articles for not meeting our language criterion, not being a primary
study, not using anti-VEGF A, concerning other cancers types besides CRC, being animal studies,
and not presenting survival analysis. The full-text reading excluded nine more articles due to lack of
survival data.
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Figure 1. Flowchart following PRISMA (Preferred Reposting Item for Systematic Reviews and Meta-
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The overview of study-quality analysis is presented in Figures 2–4. We divided this analysis into 
three parameters: high, moderate, and low quality.  
 
Figure 2. Quality evaluation of cohort studies based on Critical Appraisal Skills Programme (CASP) 
checklist. 1. Did the study address a clearly focused issue? 2. Was the cohort recruited in an acceptable 
way? 3. Was exposure accurately measured to minimize bias? 4. Was the outcome accurately 
measured to minimize bias? 5. (a) Have the authors identified all important confounding factors? 5. 
(b) Have they considered confounding factors in design and/or analysis? 6. (a) Was the follow-up of 
subjects complete enough? 6. (b) Was the follow-up of subjects long enough? 7. What are the results 
of this study? 8. How precise are the results? 9. Do you believe the results? 10. Can the results be 
applied to the local population? 11. Do the results of this study fit with other available evidence? 12. 
What are the implications of this study for practice? Note: green, yes; yellow, cannot tell. 
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2.1. Quality Assessment
The overview of study-quality analysis is presented in Figures 2–4. We divided this analysis into
three p rameters: high, moderate, and low quality.
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Figure 2. uality evaluation of cohort studies base on Critical ppraisal Skills Progra e ( S )
checklist. 1. Did the study address a clearly focused issue? 2. as the cohort recruited in an acceptable
way? 3. Was exposure accurately measured to minimize bias? 4. Was the outcome accurately measured
to minimize bias? 5. (a) Have the authors identified all important confounding factors? 5. (b) Have
they considered confounding factors in design and/or analysis? 6. (a) as the follow-up of subjects
complete enough? 6. (b) Was the follow-up of subjects long enough? 7. What are the results of this
study? 8. How precise are the results? 9. Do you believe the results? 10. Can the results be applied to
the local p pulation? 11. Do the results of this study fit with other available evidence? 12. What are the
implications of this study for pr ctice? Note: green, yes; yellow, cannot tell.
ithin the cohort studies, two of the six rticles w re classified as moderate-quality. The most
failed criteria were related to the confounding factors in the study and how precise the results were.
In the clinical trials, all articles had high quality, although some parameters failed, such as the
blindness of the study and the similarity between the groups at the start.
The case-control study had high quality, but some aspects were unclear with regard to the way
the controls and cases were selected.
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the patients who entered the trial properly accounted for at its conclusion? 4. Were patients, health
workers, and study personnel ‘blind’ to treatment? 5. Were the groups similar at the start of the trial?
6. Aside from the experimental intervention, were the groups treated equally? 7. How large was the
treatment effect? 8. How precise was the estimate of the treatment effect? 9. Can the results be applied
to the local population or in your context? 10. Were all clinically important outcomes considered? 11.
Are benefits worth the harm and costs? Note: green, yes; yellow, cannot tell.
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Figure 4. Quality evaluation of case-control study based on CASP checklist. 1. Did the study address a
clearly focused issue? 2.Did the authors use an appropriate method to answer their question? 3. Were
the cases recruited in an acceptable way? 4. Were the controls selected in an acceptable way? 5. Was
exposure accurately measured to minimize bias? 6. (a) Aside from the experimental intervention, were
the groups treated equally? 6. (b) Have the authors considered the potential confounding factors in
the design and/or in their analysis? 7. How large was the treatment effect? 8. How precise was the
estimate of the treatment effect? 9. Do you believe the results? 10. Can the results be applied to the
local population? 11. Do the results of this study fit with other available evidence? Note: green, yes;
yellow, cannot tell.
2.2. Population Description
This review included 11 studies that met our inclusion criteria with a total of population of 1345
patients, in which 785 are men and 560 are women. The age of the patients varied between 50 and
72 years. The studies used in this review were six cohorts, four clinical trials, and one case control.
Most of them only analyzed CRLM, but when they included other types of metastasis, they were lung
nodules, peritoneal nodules, or distant-lymph-node metastases.
2.3. Pharmacotherapy
The selected articles compared survival in patients with CRLM receiving treatment with
bevacizumab associated with various chemotherapy regimens. As chemotherapy, 30% f the studies
used mFOLFOX6, 30% FOLFOXIRI, and 30% oxaplatin isolated with bevacizumab. In almost articles,
the mean cycles of chemotherapy associated with bevacizumab were six. Eighty percent of the infusion
of chemotherapy associated with bevacizumab was performed prior to resection of the tumor metastasis.
In the different articles, different dosages of bevacizumab were used in the range of 5–7.5 mg/kg. In the
study by Caulet et al. (2016) [9], the way to measure the amount of bevacizumab to be used was
through its concentration in the serum, with one group receiving an amount of bevacizumab that
allowed it to reach concentration greater than 15.5 mg/L; in the other group, concentratio in the
serum was less than 15.5 mg/L.
Chemotherapy-associated bevacizumab appears to be an effective tre tment modality for treating
liver metastasis fr m colorectal cancer, and its administration significantly extends su vival when
compared with chemother py alone. It was generally agreed that b vacizumab inhibits tumor
angi gen si , decreases tumor-i ters tial-flu d pressure that enables enhanced drug uptake by tumor
cells, and protects against hepatic sinusoidal obstruction syndr .
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Regarding liver metastasis, one of the studies affirmed that complete remission was higher for
those with exclusively hepatic metastasis than those with nonexclusively hepatic metastasis. So,
bevacizumab therapy for CRLM allows besides better survival rates, better outcomes from resection of
metastasis with complete remission, and it is a feasible, safe, and effective neoadjuvant regimen in
patients with CRLM undergoing potentially curative liver resection [10].
However, one of the studies mentioned that the addition of bevacizumab to adjuvant hepatic
arterial infusion (HAI) plus systemic therapy after liver resection did not seem to increase survival, but
appeared to increase biliary toxicity [11].
2.4. Survival Outcome
Practically every study, more precisely 73% [4,5,9,10,12–15], concluded that bevacizumab therapy
for the treatment of CRLM was effective and significant for both OS and/or progression-free survival
(PFS), apart from three. These latest ones, groups receiving chemotherapy associated with bevacizumab,
obtained worse survival rates than those who received the therapy without the drug being studied.
To evaluate OS, the different articles used several methods and measures. Ninety percent of the
studies calculated the OS values, with an average of 32.5 months. In addition to this value, we were
able to extract the survival values at three and five years from 55% of the articles, with a mean value
of 80% and 56%, respectively. Only 40% of the authors collected PFS parameters, and the rest chose
others: disease-free survival (DFS) in 30%, recurrence-free survival (RFS) in 10%, and the remaining
only calculated either isolated OS or nothing, only concluding if the application of bevacizumab would
or not have a positive effect on the patients.
In the trial by Caulet et al. (2016) [9], there were significant differences in median OS and median
PFS between two groups with different doses of bevacizumab, these values being superior in the group
whose dose was superior.
Chen H et al. (2016) [13] compared two groups: in Group 1, target vessel regional chemotherapy
(TVRC) treatment was without bevacizumab; in Group 2, TVRC was associated with bevacizumab.
Intrahepatic and extrahepatic time to progression was significantly different in the two groups, and
much higher in the bevacizumab group. This indicated that bevacizumab could not only inhibit
intrahepatic but also extrahepatic tumor vessels, thus postponing tumor progression. There was also
a significant difference between the group that used bevacizumab and the one that did not in terms
of survival.
Of the studies, 27% reported worse results in groups that used bevacizumab than those that did not,
they being Van der Pool et al. (2012) [16], Kemeny et al. (2010) [11], and C. R. Scoggins et al (2009) [17].
In the first, the non-bevacizumab group (1) three-year DFS was 32%, and in the bevacizumab group
(2) it was 23%, even though this result was not significant (p = 0.35). The second author confirmed
that one-year RFS was 83% and 71%, and four-year RFS was 46% and 37% for non- bevacizumab
(bev) and bev groups, respectively. The last one denoted that DFS of preoperative chemotherapy with
the bevacizumab group [1] was 40 months, while the nonpreoperative-chemotherapy group [2] had
median DFS of 56 months; again, these results were not significant (p = 0.25). In addition, OS was 56
months for Group 1 compared with 65 months for Group 2 (p = 0.30).
2.5. Included-Study Literature Search Results
The literature-search results, based on the applied keywords, and inclusion and exclusion criteria,
are shown in Tables 1 and 2.
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Table 1. Population description.








et al. [9] 2016 Cohort No info.
Eligible patients (18–80 years old) had histologically
confirmed colorectal cancer (CRC) with at least one
instance of hepatic metastasis detected by
ultrasonography, life expectancy of more than two
months, a World Health Organization (WHO)
performance status of two or less, and were treated
with first-line treatment by a bevacizumab-based
chemotherapy.
137 58–72 79 58
Umehara
et al. [4] 2016 Cohort No info.
Patients were required to be between the ages of
18–80 years and to have histologically proven
colorectal cancer with a World Health Organization
performance status of two or less, potentially
resectable liver metastases, and no detectable
extrahepatic tumors.





Brain metastasis; ileus; inextricable
obstructive jaundice; abdominal
and pelvic effusion; and
breastfeeding or pregnant women.
Patients diagnosed with colorectal cancer with liver
metastasis; number of instances of liver metastasis of
at least two or one, but difficult to resect by
conventional surgery; after failure of first- or
second-line or more systemic chemotherapy;
expected lifetime of at least three months; no
contraindication to treatment with chemotherapy;
and age of at least 18 years old.
63 40–80 41 22
Rouyer
et al. [10] 2016 Cohort
They were opposed to the
collection of data regarding
themselves or if they participated
in a clinical trial, unless they were
receiving a standard treatment
(control arm) in an open-label
Phase III study.
Proven diagnosis of CRC with nonresectable
metastases, and treated with bevacizumab as first-line
palliative therapy (nonresectability was documented
in the medical files according to the multidisciplinary
staff); when applicable, ≥6-month interval between
adjuvant chemotherapy for primary tumor and
initiation of bevacizumab; no chemotherapy for
metastatic disease before the initiation of
bevacizumab; and no prior history of treatment with
bevacizumab, including as part of a clinical trial and
during the period when bevacizumab was available
under temporary use authorization (Autorisation
Temporaire d’Utilisation).
360 61–64 221 149
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et al. [14] 2014
Clinical
trial No info.
Patients with histologically proven colorectal cancer
and at least one measurable lesion in the liver (with
no nonhepatic distal metastasis/relapse) were eligible
for this study if they met all of the following criteria:
H2 or H3 CRC liver-metastasis (CRLM; either
synchronous or metachronous); age ≥20 and ≤75
years; no prior chemotherapy except adjuvant
chemotherapy if ended ≥6 months before study entry;
no prior radiotherapy for advanced/recurrent
colorectal cancer; Eastern Cooperative Oncology
Group performance status (PS) 0 to 1; life expectancy
estimated ≥ 3 months; adequate bone marrow and
renal function.
40 37–74 29 11
Shindoh
et al. [12] 2012 Cohort No info. No info. 209 58 124 85
Van der
et al. [16] 2012 Cohort
Patients who had undergone
portal-vein embolization (PVE) or
portal-vein ligation (PVL), and
patients who had been treated with
other chemotherapeutics besides
oxaliplatin-based chemotherapy.
Macroscopic radical resection of the liver metastases
and the use of oxaliplatin-based CTx in neoadjuvant
setting.
104 41–79 62 42
Kemeny
et al. [11] 2010
Clinical
trial
Extrahepatic disease, prior hepatic
radiation, infection, history of
stroke or transient ischemic attack,
history of serious systemic illness,
Karnofsky performance score <60,
other malignancy (within five
years before study entry), WBC
count 3000/µL, absolute neutrophil
count <1500/µL, platelet count
≤75,000/µL, and total bilirubin
>2.0 mg/dL
Histologically confirmed colorectal adenocarcinoma
with fully resected liver metastases. 73
29 persons >
or = to 60
years
25 48
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Patients included were retrospectively assessed for
eligibility using well-established databases in each
respective center.
90 54–65 50 40
Scoggins
et al. [17] 2008 Cohort
Patients treated with RFA only
were not included.
Only patients who underwent hepatic resection or
combined resection/radiofrequency ablation (RFA)
for metastatic colorectal cancer between 1996 and










et al. [5] 2008
Clinical
trial
Prior chemotherapy for metastatic
disease; prior history of bleeding
diathesis or coagulopathy; clinical
evidence of CNS metastases;
history of thromboembolic or
hemorrhagic events within 6
months before treatment; clinically
significant cardiovascular disease.
Patients with histologically confirmed resectable CRC
liver metastases who were at high risk of early
recurrence defined as one or more risk factors
according to Fong et al. These risk factors included:
synchronous liver metastases; metastatic disease
developed within one year after primary resection;
lymph-node-positive primary tumors; more than one
instance of liver metastasis; liver metastasis larger
than 5 cm; and a positive carcinoembryonic antigen
level. Patients were also required to have an Eastern
Cooperative Oncology Group (ECOG) performance
status of 0 to 1, adequate bone-marrow reserve, and
adequate renal and hepatic function.
56 61.5 32 24
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Table 2. Study summary information.












There were significant differences in overall survival (OS; P < 0.001) and in PFS (P =
0.001) between the two groups. OS was 17.3 months for patients with bevacizumab
(Bev) lower than 15.5 mg/L, and 33.9 months for patients with Bev higher 15.5 mg/L.
Median PFS (95% CI) was 8.7 months for patients with Bev lower than 15.5 mg/L,
and 13.2 months for patients with Bev higher 15.5 mg/L. Increased drug exposure
was shown to be associated with better clinical response and/or survival.
Umehara








Three-year OS rate was 73.9%, and five-year OS rate was 62.5%. Disease-free
survival (DFS) was significantly longer after mFOLFOX6 + Bev therapy compared
to mFOLFOX6 therapy alone (p = 0.015). Optimal morphological response was
associated with high five-year OS and DFS rates of 74% and 47%, respectively, and
was observed in 47% of patients treated with bevacizumab and 12% of patients
treated without bevacizumab. In the current study, we found no significant
improvement in OS in patients treated with mFOLFOX6 + Bev compared to those
treated with mFOLFOX6 alone (P = 0.23). Nevertheless, the observed increase in








Group 1: mFolfox6 +
bevacizumab 100 mg.
Group 2: mFolfox6 +
bevacizumab 400 mg.
6
Two groups: in Group 1, target vessel regional chemotherapy (TVRC) treatment
was without bevacizumab; in Group 2, TVRC was associated with bevacizumab.
Time to progression of intrahepatic metastases (TTPIHM) was 3.53 and 6.23 (P =
0.018), and time to progression of extrahepatic metastases was 4.17 and 5.63 (P =
0.049) months in Groups 1 and 2, respectively. This indicated that bevacizumab
could not only inhibit intrahepatic but also extrahepatic tumor vessels. and there







bevacizumab. Maximum of 8.
They observed that complete remission after surgery was high, in particular for
patients with exclusively hepatic metastases, in line with induction chemotherapy
associated with targeted therapy such as bevacizumab. These results support the
idea that patients with exclusive hepatic metastases are better candidates to benefit










Stable disease was achieved in 55.0% of patients, and tumor-control rate was 85.0%.
Median PFS of all patients (n = 40) was 9.7 months (95% CI = 6.2–11.8 months).
Estimated one-, two- and three-year PFS was 35.0%, 22.5%, and 12.5%, respectively.
Median survival time (MST) was 33.0 months (95%CI = 22.8 months—not reached).
Estimated one-, two- and three-year OS was 87.5%, 62.3%, and 49.3%, respectively.
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This analysis determined that CT morphologic response to preoperative
chemotherapy is a strong predictor of long-term outcomes after surgery in patients
treated with or without bevacizumab. Optimal morphologic response was
associated with high five-year OS and DFS rates of 74% and 47%, respectively. (95%
CI: 1.46 to 4.49)On multivariate analysis, bevacizumab was strongly associated with
optimal morphologic response (odds ratio, 6.71)
Van der






Estimated three-year disease-free survival in Groups 1 (non-bevacizumab) and 2
(bevacizumab) was 32% and 23%, respectively (P = 0.35). Bevacizumab added to
oxaliplatin-based CTx may protect against moderate sinusoidal dilatation without
significantly influencing morbidity.
Scoggins







therapy with or without
bevacizumab
6
Addition of Bev to adjuvant hepatic arterial infusion (HAI) plus systemic therapy
after liver resection did not seem to increase RFS or survival but appeared to
increase biliary toxicity. One-year RFS was 83% (95% CI, 66% to 92%) and 71% (95%
CI, 52% to 83%), and four-year RFS was 46% and 37% (P=.4) for non-bev and bev
arms. Four-year survival was 85% (95% CI, 60% to 95%) in the non-bev arm, and
81% (95% CI,56%to 93%) in the bev arm (log-rank test P = 0.5)
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Overall morbidity rate was 56% (Bev) versus 40% (control); adjusted OR 1.74, 95%
CI 0.71–4.28; p = 0.23. Mortality was 0 versus 2 in Bev and control groups,
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DFS and OS rates of preoperative-chemotherapy group were lower than in the
nonpreoperative-chemotherapy group, although this was not statistically
significant. DFS of the preoperative-chemotherapy group was 40 months, while the
nonpreoperative-chemotherapy group had a DFS of 56 months. OS was 56 months
for the preoperative-chemotherapy group compared with 65 months for the
nonpreoperative-chemotherapy group. Five-year DFS and OS for the entire cohort
were 48% and 53%, respectively.
Gruenberger
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A total of 41 patients responded (objective response rate, 73.2%); five patients had a
complete pathologic response (8.9%), and 36 had a partial response. Twelve
additional patients (21.4%) had stable disease, and overall disease-control rate was
94.6%. This trial showed that perioperative chemotherapy followed by surgery and
postoperative chemotherapy significantly improved three-year PFS in all eligible
patients (36.2% v 28.1%; P 0.041).
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3. Discussion
This review included 11 studies with a total of population of 1345 patients, in which 785 are
men and 560 are women. The age of the patients varied between 50 and 72 years. Most of them only
analyzed CRLM, but some had extrahepatic metastasis such as lung nodules, peritoneal nodules, or
distant-lymph-node metastasis. Regarding the quality of the studies, two of the eleven articles were
classified as moderate-quality, and the other nine as high-quality.
The selected articles compared survival in patients with CRLM receiving treatment with
bevacizumab associated with various chemotherapy regimens. More than 50% of patients with
CRC develop liver metastases over the course of their pathology, which leads to the death of more
than two-thirds of these patients [18,19]. Liver-resection surgery in patients with isolated metastatic
liver disease remains the only option for a possible cure. However, even when resection is associated
with modern systemic adjuvant regimens, it is only curative in 20% of patients [18–20]; 70% of patients
experience disease recurrence, mainly in the liver [18].
Considering the mechanism of action of bevacizumab, almost all articles concluded that this drug
improves prognostic survival by inhibiting tumor angiogenesis, a mechanism that plays an important
role in malignant-tumor growth and persistence. Therefore, it compromises the survival of cancer cells,
blocking their growth. It also decreases tumor interstitial fluid pressure that enables enhanced drug
uptake by tumor cells and leads to an overgrowth of fibrosis at the expense of viable tumor cells.
In 73% of the included articles, chemotherapy with bevacizumab appeared to be an effective
treatment modality for treating CRLM, and its administration significantly extended survival. In this
review, we saw that the dose of bevacizumab could interfere with survival rate; a higher dose of this
drug has better results in terms of efficacy and is associated to a longer survival. This suggests that
increasing exposure to bevacizumab may increase its efficacy, and it is associated with a better clinical
response of CRLM patients.
For example, a small Phase II study of bevacizumab combined with 5-FU and leucovorin suggested
that a bevacizumab dose of 10 mg/kg was more effective than 5 mg/kg. Bevacizumab concentration
higher than 15.5 mg/L was also associated with almost doubled OS when compared with patients
whose concentration was below that value (33.9 vs. 15.5 months; p = 0.006) and PFS (13.2 vs. 8.7 months;
p = 0.0039) [9]. These findings are in accordance with other analyses that designated that the rate of
optimal morphologic response was moderately low (12%) in patients treated without bevacizumab
when in comparison with patients treated with bevacizumab (47%); this means that it is toughly related
with prime morphologic response (odds ratio, 6.71) [12].
On the other hand, not all articles showed a positive outcome in terms of survival. In 27% of the
reviews, the groups receiving chemotherapy associated with bevacizumab did not obtain positive
survival-outcome rates. In fact, those who received the therapy without the drug being studied
had better prognosis. Despite this, these results were not significant, that is, although they did not
improve the outcome, they did not worsen it either. Studies and results demonstrated by these
articles were the first to be carried out, and, in the last decade, new innovative discoveries emerged.
So, we concluded that the evolution of the investigation in this area shows the administration of
bevacizumab has a positive impact on patient survival. In this group of articles, one of them was
classified as moderate-quality.
Not all studies showed their follow-up time, which was important information to compare all
of them, since it could have a huge effect on survival rate. Moreover, when mentioned, it would be
similarly impossible to compare considering that different studies used different follow-up times. About
the treatment itself, it was not uniform analysis in terms of when chemotherapy was administered
(after or before surgery). In addition, not all studies performed resection of liver metastasis, which
compromised the comparison of the studies, since this surgery is seen as the most effective treatment
for CRLM, and potentially the only curative one.
When comparing the results of the studies, we noticed some difficulties because they used different
measures in order to evaluate survival. Most studies did not clearly define if CRC metastasis was
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synchronous or metachronous, isolated or with the involvement of another organ; they also did not
clearly define the outcomes, namely, OS, PFS, and DFS. This may constitute a bias due to not being
possible to compare those measures between them because they evaluate different parameters. One
article did not measure survival, but just indicated if the addition of bevacizumab was beneficial or not
in terms of overall disease control. In addition, not all studies defined the specific cause of death of the
patient when they evaluated survival, so it cannot be confirmed that patients died only due to the
CRLM, or if death was from other causes. Bevacizumab has also never been studied in isolation, but
always associated with other drugs.
It is necessary to standardize the methodologies of studies that aim to evaluate the impact of the
administration of bevacizumab on the survival of patients with CRLM. Furthermore, it is necessary to
define the parameters to be evaluated in each study, defining, for example, the follow-up time and the
cause of the patient’s death in order to better calculate the survival rate, and provide a comparison
between the produced literature.
Bevacizumab plays an important role in the treatment of CRLM, and it can improve patient
survival, although there were three studies showing no positive outcomes. We conjectured that it is
necessary to standardize and universalize some of the most important and essential parameters for the
evaluation of survival as a main outcome in studies of this kind, such as overall survival, follow-up
time and if this was performed in the most correct way, if patients in had comorbidities that would
influence their prognosis, and the specific cause of death in order to produce a more solid literature.
This area requires more studies, and it would be advantageous and enriching to carry out future
meta-analysis on this topic to evaluate the concordance and relationship between various studies.
Recommendations
Chemotherapy associated with bevacizumab is increasingly used in association with surgery, not
only in the neoadjuvant treatment of patients with liver metastases that would initially be unresectable
in order to make them resectable, but also in patients with resectable liver metastases with the objective
of reducing the risk of recurrence.
As a guideline, in patients with resectable CRLM, perioperative chemotherapy (before and after
resection surgery) has become the standard treatment in many studies. In patients with unresectable
CRLM at diagnosis, the combination of neoadjuvant chemotherapy with bevacizumab and surgery
is a good way to increase the survival of these patients and improve their prognosis. However, it is
essential that these patients are carefully monitored, and surgery is performed as soon as metastases
become resectable.
On the other hand, there are several questions that remain unanswered and that still need reliable
studies, such as how long before surgery to perform neoadjuvant chemotherapy, what the ideal number
of cycles are, and what the interval between surgery and the new treatment of chemotherapy is. We
also know that a higher dose of bevacizumab is associated with better a clinical outcome, but we do
not objectively know what the most correct dose is, considering that it was not uniform in all studies.
Nevertheless, there is a parameter that is essential, particularly at a time when more combinations
of chemotherapeutic agents, and more developed surgical procedures and complementary diagnostic
tests are appearing: the therapeutic scheme and monitoring of each patient must be carefully decided
and studied by competent and dedicated multidisciplinary teams.
4. Materials and Methods
4.1. Criteria for Considering Studies for this Review
4.1.1. Types of Studies
Study that analyzed the effects on survival of adding bevacizumab to chemotherapy in patients
with CRLM.
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4.1.2. Types of Participants
Studies including participants with colorectal cancer with at least liver metastasis.
4.1.3. Types of Interventions
Trials investigating treatment with bevacizumab at any dosage and in any formulation.
4.2. Search Methods for Identification of Studies
4.2.1. Data Sources and Searches
A systematic review of the literature was made following a predefined protocol, with the objective
of identifying studies appraising and comparing the survival of patients with colorectal cancer and
liver metastasis who were treated with chemotherapy with bevacizumab.
The Pubmed and Google Scholar databases were searched for eligible articles (from inception up
to 2 April 2019). The following keywords were used in the search: “anti-VEGF”, “colorectal cancer”,
“hepatic metastasis”, and “survival”. If there were repeated publications, we selected the most recent
articles and those that presented more data. Ultimately, we used the “snowball” method aiming to
identify additional relevant papers by tracking the references and citations of found articles.
4.2.2. Selection of Studies, and Data Extraction and Management
Two of the review authors (I.N. and B.C.) independently evaluated all yielded titles and abstracts
for eligibility. We resolved disagreements by consensus or by involvement of a third review author
(S.F.M.). In the case of a few articles describing the same trial, we selected the conclusive article as the
main report, and analyzed the remaining articles for complementary information on clinical outcomes,
descriptions of study participants, or design characteristics.
We extracted the type of control used, author names, year of publication, sample size, primary
endpoint, results on OS and PFS, and, when these data were not available, we extracted disease-free
survival (DFS) or anything else that gave us information on survival, such as dosage and number of
bevacizumab cycles, and certain participant characteristics such as age and gender. We also extracted
important conclusions from the publication status.
4.2.3. Study-Eligibility Criteria
Studies investigating the associations between anti-VEGF A (bevacizumab) and OS in patients
with hepatic metastatic colorectal cancer were initially reviewed. Two of the review authors (I.N. and
B.C.), working separately and in parallel, checked the abstracts, and then fully accessed and reviewed
only articles that met the established inclusion and exclusion criteria.
Inclusion criteria: studies including patients with CRLM, patients receiving anti-VEGF
(bevacizumab) as treatment, overall survival as an outcome; regarding language restrictions, only
articles in English were accepted.
Exclusion criteria: types of paper that were not primary studies, studies that did not have patients
assigned to anti VEGF-A (bevacizumab), not having colorectal cancer with liver metastasis; papers
that did not measure survival as an outcome, studies not performed on humans, and papers that were
not in the English language.
4.2.4. Quality Assessment of Included Studies
Two of the review authors (I.N. and B.C.) independently assessed the adequacy of randomization,
blinding, and analyses, verifying methodological validity for every study that met the inclusion criteria.
Any disagreements were resolved through consensus-based discussion or with a third review author
(S.F.M.). Quality assessment of the included studies was based on recommendations given by the
Critical Appraisal Skills Program (CASP) checklists for cohort [21], randomized controlled Trials [22],
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and case-control [23] studies. On the basis of information given by the journal publications, we judged
each domain in each study as high-, moderate- and low-quality.
4.2.5. Data Synthesis
The primary endpoints were PFS and OS. OS was characterized as the length of time since
randomization to the occurrence of death. PFS illustrated the length of time since randomization to the
first occurrence of progression, relapse, or death from any cause. When these were not available, we
extracted the DFS, which was measured from the date of hepatic resection until the date of radiographic
detection of recurrence or last follow-up. Benefits in OS and PFS from adding bevacizumab to standard
chemotherapy regimens had their values assessed as a percentage, their respective 95% confidence
intervals (CI), and the published Kaplan–Meier curves to collect any data that would help us understand
the influence of this therapy on survival.
5. Conclusions
Our data suggested that bevacizumab plays an important role in the treatment of CRLM,
as recommended by international guidelines. To obtain fewer conflicting data, it is necessary that
these studies clearly define the parameters to be evaluated and to standardize the methodologies of
the studies.
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